ProText Mobility Inc (TXTM)

[stervc]

Huge TXTM & CIDP Legitimacy Confirmation...

TXTM and what they are doing is very real and should not be challenged for legitimacy. Courtesy of the outstanding research provided by La Dolce Vita in the post and news below definitely confirms that the Centre International de Developpment Pharmaceutique (CIDP) is going to conduct a human clinical trial with the TXTM product Phytofare® which is absolutely huge in my opinion for adding even more legitimacy:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=131743382

CIDP was selected by the prestigious Harvard University to be part of the Technology, Innovation, and Entrepreneurship in Africa Programme to understand the legitimacy and quality of involvement CIDP brings to TXTM:

http://www.cidp-cro.com/news/cidp-part-harvards-executive-program-shaping-africas-future
CIDP’s project, in collaboration with The University of Mauritius (UOM) has been selected by the prestigious Harvard University to be part of the Technology, Innovation, and Entrepreneurship in Africa Programme. This ambitious project entitled: “Africa’s Green Gold...

http://www.harvard.edu/

http://www.protextm.co/


http://m.marketwired.com/press-release/protext-mobility-signs-agreement-with-leading-research-center-cidp-conduct-diabetes-pinksheets-txtm-2214073.htm
Protext Mobility Signs Agreement With Leading Research Center, CIDP, to Conduct Diabetes Human Clinical Trial

BOCA RATON, FL--(Marketwired - May 4, 2017) - Protext Mobility, Inc. (OTC PINK: TXTM) ("Protext" or "the Company"), a biotech company engaged in the development of pharmaceutical applications with highly bioavailable Phytofare® extracts, announced today that it has signed an agreement with the Centre International de Developpment Pharmaceutique (CIDP) to conduct a human clinical trial with its product Phytofare® Catechin Complex, in the country of Mauritius. ...

Based on the outcome of the clinical studies, the company intends to submit its findings to the United States FDA under their Botanical Drug classification to obtain clearance to market Phytofare® specifically for treating Type II diabetes. Botanical drugs are subject to fewer requirements by the FDA and can obtain clearance much faster and with significantly less cost. ...

Until we obtain an FDA clearance specific to diabetes, we intend to commence selling the product worldwide using "structure function claims" about the general benefits of Phytofare® in regulating glucose levels."

Now read below to see what positive comments Mrs. Vandana Mungroo, Head of clinical operations CIDP, had to say about TXTM and its Phytofare:

http://m.marketwired.com/press-release/protext-mobility-signs-agreement-with-leading-research-center-cidp-conduct-diabetes-pinksheets-txtm-2214073.htm
Mrs. Vandana Mungroo, Head of clinical operations CIDP, who will oversee the human clinical trial in Mauritius, added, "We're excited to work with Protext on a project that is so critical to the health of Mauritius, where an estimated 25% of the population suffers from Type II Diabetes. Having a complex of active antioxidants available to help regulate glucose levels would be a significant benefit to developing countries where the populations are hardest hit. Multiple third-party studies indicate that green tea catechins show potential for regulating glucose levels however; human clinical research in this field has been hampered due to poor bioavailability and high dosage. We now believe that the higher bioavailability of Phytofare® may overcome these challenges and lead to an all-natural inhibitive and preventative treatment of the disease."

http://www.cidp-cro.com/
Centre International de Développement Pharmaceutique (CIDP) is a private and independent CRO carrying out high performance research and clinical activities for pharmaceutical, medical device, nutrition and cosmetic industries. CIDP is ISO 9001:2015 certified.

We serve our clients both as a service provider upstream through Research and Preclinical activities and downstream through Regulatory affairs, Biostatistics & Data Management and Clinical Research.

The geographical locations of our centres enable the access to a wide panel of patients. This allows us to undertake multi-centric trials with a rapid recruitment process in a secured and adapted environment.

Recognised for its expertise, CIDP forms part of the IBL group.
IBL is ranked among the 16 most dynamic and fast growing companies in Africa according to the World Economic Forum in 2014. Ranked number 1 in the TOP 100 Mauritian companies and number 3 in the Indian Ocean, IBL has recently decided to invest in Life sciences through its subsidiary: IBL Life. Its ambition is to become the essential starting point in this growing sector.

https://www.iblgroup.com/en/


https://www.iblgroup.com/en/ibl-together-group-mauritian-holding/history-values-investment-africa-mauritius.html

v/r
Sterling